Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NRX Pharmaceuticals (NRXP) Equity Average (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Equity Average for 2 consecutive years, with -$20.8 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 0.84% to -$20.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.8 million through Dec 2025, up 0.84% year-over-year, with the annual reading at -$19.6 million for FY2025, N/A changed from the prior year.
  • Equity Average for Q4 2025 was -$20.8 million at NRX Pharmaceuticals, up from -$30.7 million in the prior quarter.
  • The five-year high for Equity Average was -$16.7 million in Q2 2024, with the low at -$30.7 million in Q3 2025.